This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
What good is AI in healthcare if it doesn’t improve financial margins? The question is getting posed in the C-suites of provider organizations and insurance companies.
Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.
The new platform provides users with real-time access to high-quality electrocardiograms and patient data. The goal is to ensure everyone is on the same page at all times, with no unnecessary delays.
The annual list is based on resources, services provided, outcomes data and survey responses from thousands of physicians. Did your facility make the cut?
ISC 2024 in Phoenix has already featured several eye-opening late-breaking presentations. One study, for example, found that positioning a stroke patient's head differently before surgery can significantly decrease the risk of neurological complications.
It’s not easy to get patients, providers, payers, vendors and regulators to agree on any one aspect of healthcare delivery. But the CDRH recently managed to get everyone to settle on a working definition of transparency.
One of the world's leading heart hospitals is seeing significant growth. This represents the first time it has hired four new cardiothoracic surgeons in a single 12-month period.
Americans trust nurses and doctors less than they did a few years ago, but both professions still make the top five among 23 wide and varied work roles.
The latest COVID-19 vaccine began entering recipients’ bodies last September. Now comes early CDC data supporting the formulation’s general effectiveness.
Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.
The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.